Skip to main content
Caplight Logo









YUMAB GmbH

YUMAB GmbH

Private
BraunschweigHealthcare & Life Scienceshttps://www.yumab.com/

Last Round

Grant

Jan 27, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

YUMAB GmbH is a biotechnology company that provides contract research, technologies, and R&D services for the development of fully human therapeutic antibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

monoclonal antibodiesphage displayantibody discoverycontract research organizationCROantibody engineeringdrug discoverybiotech servicesaffinity maturationtherapeutic antibodybiologics discoveryin silico optimizationantibody librarydrug developmentbiotech outsourcing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

YUMAB GmbH Comparables

Compare YUMAB GmbH with similar companies based on industry and business-model similarity.

YUMAB GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Isogenica
83%
Adimab
78%
Twist Bioscience Corporation
77%

YUMAB GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 27, 2025
GrantOct 17, 2023
GrantJul 19, 2023

Key People

Founding team and executive leadership

Thomas Schirrmann

CEO

Executive Team

YUMAB GmbH Investors

Notable investors and investment history

YUMAB GmbH investors
InvestorRounds
Bundesministerium für Bildung und ForschungGrant
NBankGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Monthly visitors increased 325% MoM, reaching 204.

  • Jul 3, 2025

    Monthly visitors grew 308% MoM, reaching 4.9K.

YUMAB GmbH Filings

Explore SEC and related filing metadata, where available.

YUMAB GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about YUMAB GmbH's valuation, stock price, and market status.

Is YUMAB GmbH a public or private company?

YUMAB GmbH is a private company.

What is the current stock price of YUMAB GmbH?

YUMAB GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is YUMAB GmbH worth (valuation)?

Valuation information for YUMAB GmbH is not publicly available.

Can I buy YUMAB GmbH stock?

YUMAB GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was YUMAB GmbH's last funding round?

YUMAB GmbH's most recent funding round was Grant on January 27, 2025.

Who are the main investors in YUMAB GmbH?

Key investors in YUMAB GmbH include Bundesministerium für Bildung und Forschung, NBank.

Will YUMAB GmbH IPO soon?

No public IPO plans have been announced for YUMAB GmbH.

How can I track YUMAB GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor YUMAB GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBraunschweig
Employee Range16
Year Founded2012
Last FundingJan 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?